Metformin and bladder cancer: Drug repurposing as a potential tool for novel therapy: A review |
| |
Authors: | Yunzhu Feng Benzhong Jia Zhiyong Shen |
| |
Affiliation: | a School of Clinical Medicine, Guizhou Medical University, Guiyang City, Guizhou Province, China;b Department of Urology, Affiliated Hospital of Guizhou Medical University, Guiyang City, Guizhou Province, China;c Department of Urology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang City, Guizhou Province, China. |
| |
Abstract: | Bladder cancer (BC) is a common type of cancer worldwide. Currently, the gold standard treatment is transurethral resection of bladder tumor (TUR-Bt) accompanied by intravesical Bacillus Calmette–Guérin (BCG) instillation for patients with middle-to-high-risk non-muscle-invasive bladder cancer (NMIBC). However, intravesical BCG therapy fails in almost 50% of high risk cases, leading to NMIBC persistence or early recurrence. In these patients, the gold standard remains radical cystectomy; however, it can seriously affect the patients’ quality of life. Moreover, for patients with muscle-invasive bladder cancer (MIBC), the 5-year survival rate after radical cystectomy with neoadjuvant chemotherapy remains low. Recent discoveries have paved the way for a new era in BC treatment. Metformin is the most widely used oral hypoglycemic drug in clinical practice, being mostly used in the treatment of type 2 diabetes. Epidemiological studies have demonstrated that metformin exerts a potentially positive effect on reducing the incidence and mortality of cancer; therefore, a increasing number of studies have investigated the potential anticancer effects of metformin and its mechanisms of action. This review aims to summarize the evidence for the role of metformin in bladder cancer therapy, including how metformin mediates bladder cancer cell apoptosis. |
| |
Keywords: | apoptosis bladder cancer cell cycle metformin signaling pathway |
|
|